# US 2022/0031869 A1 · Nanocarrier systems for imaging and delivery of active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031869 A1
- Document ID: US20220031869A1
- Status: Published application
- Kind: A1
- Application number: 17/296,379
- Filed: 2019-11-26
- Published: 2022-02-03
- Earliest claimed: 2018-11-28
- Assignees: Kansas State University Research Foundation
- Applicants: Kansas State University Research Foundation
- Inventors: Santosh Aryal; Arunkumar Pitchaimani; Tuyen DT Nguyen
- Web page: https://patentgrep.com/patent/US20220031869A1

## CPC

- A61K 49/1812: {liposomes, polymersomes, e.g. immunoliposomes}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 47/6911: {the form being a liposome}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 49/1878: {the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating}
- A61K 49/1896: {not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Synthetic nanocarrier constructs and related compositions comprising a lipid-based bilayer membrane infused with one or more NK-92 cell membrane proteins, which encapsulates a liquid receiving interior space or coats at least a portion of a solid core. Methods of targeted delivery of an active/diagnostic/imaging agent to a specific cell type or a region of a patient by administering a plurality of nanocarrier constructs to the patient. MRI imaging methods and novel MRI contrast agent constructs are also disclosed.

## Claims

### Claim 1

A synthetic nanocarrier construct comprising a lipid-based bilayer membrane infused with one or more NK-92 cell membrane proteins.

### Claim 2 (depends on 1)

The nanocarrier construct of claim 1, wherein said NK-92 cell membrane proteins are surface protein receptors.

### Claim 3 (depends on 2)

The nanocarrier construct of claim 2, wherein said surface protein receptors are CD56, NKG2-D, NKp30, NKp44, CD16, or a combination thereof.

### Claim 4 (depends on 1)

The nanocarrier construct of claim 1, said lipid-based bilayer membrane comprising a mixture of lipids and NK-92 cell membrane phospholipids.

### Claim 5 (depends on 4)

The nanocarrier construct of claim 4, wherein said lipids are selected from the group consisting of phosphoethanolamines, phosphatidylcholines, phosphoglycerols, phosphatidic acids, Sphingolipids, Sphingomyelin, and combinations thereof.

### Claim 6 (depends on 4)

The nanocarrier construct of claim 4, wherein said membrane comprises at least two different types of lipids.

### Claim 7 (depends on 4)

The nanocarrier construct of claim 4, further comprising cholesterol and/or oleic acid.

### Claim 8 (depends on 1)

The nanocarrier construct of claim 1, wherein said NK-92 cell membrane proteins are located at the exterior surface of the lipid bilayer, in the core of the lipid bilayer, and/or at the interior surface the lipid bilayer.

### Claim 9 (depends on 1)

The nanocarrier construct of claim 1, wherein said membrane encapsulates a liquid-receiving interior space.

### Claim 10 (depends on 9)

The nanocarrier construct of claim 9, further comprising one or more active agents dispersed in said liquid-filled interior space.

### Claim at position 11

-12. (canceled)

### Claim 13 (depends on 1)

The nanocarrier construct of claim 1, wherein said membrane coats at least a portion of a solid core.

### Claim 14 (depends on 13)

The nanocarrier construct of claim 13, wherein said solid core is a polymeric or metal nanoparticle.

### Claim at position 14

-16. (canceled)

### Claim 17 (depends on 1)

The nanocarrier construct of claim 1, said membrane having an exterior surface comprising one or more imaging agents or detectable moieties.

### Claim 18

(canceled)

### Claim 19 (depends on 14)

The nanocarrier construct of claim 14, wherein said membrane comprises an active agent incorporated therein.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A method of targeted delivery of an active/diagnostic/imaging agent to a specific cell type or a region of a patient, said method comprising administering a plurality of nanocarrier constructs of claim 1 to said patient.

### Claim 22 (depends on 21)

The method of claim 21, wherein said nanocarrier constructs accumulate in and near an area of infection, inflammation, and/or cancerous tissue in said patient.

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The method of claim 21, wherein said nanocarrier constructs fuse with said specific cell type and release an active agent directly into the fused cell.

### Claim 25 (depends on 21)

The method of claim 21, wherein said patient has is or suspected of having cancerous or precancerous tissue or cancer cells, wherein said nanocarrier constructs accumulate in said cancerous or precancerous tissue or cancer cells.

### Claim at position 24

-27. (canceled)

### Claim 28 (depends on 1)

A diagnostic and/or therapeutic composition comprising a plurality of nanocarrier constructs according to claim 1, optionally dispersed in a pharmaceutically-acceptable carrier or excipient.

### Claim 29 (depends on 1)

An MRI imaging method for detecting cancerous or precancerous tissue or cancer cells in a mammal comprising:
(a) administering to the mammal a plurality of nanocarrier constructs according to claim 1, said nanocarrier construct comprising at least one imaging contrast agent, wherein said nanocarrier constructs accumulate in cancerous or precancerous tissue or cancer cells in said mammal;
(b) locating said nanocarrier constructs in a region of interest in the mammal suspected of having said cancerous or precancerous tissue or cancer cells;
(c) transmitting radio frequency pulses to said region of interest; and
(d) acquiring MR image data of the region of interest, said MR image data comprising T1 data.

### Claim at position 27

-35. (canceled)
